On Friday, Adma Biologics Inc (NASDAQ: ADMA) was 2.61% up from the session before settling in for the closing price of $19.32. A 52-week range for ADMA has been $3.60 – $23.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 73.26% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 496.15%. With a float of $228.37 million, this company’s outstanding shares have now reached $236.38 million.
In an organization with 624 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 48.79%, operating margin of 30.01%, and the pretax margin is 19.16%.
Adma Biologics Inc (ADMA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adma Biologics Inc stocks. The insider ownership of Adma Biologics Inc is 3.39%, while institutional ownership is 88.42%. The most recent insider transaction that took place on Nov 22 ’24, was worth 317,250. In this transaction CFO and Treasurer of this company sold 15,000 shares at a rate of $21.15, taking the stock ownership to the 199,433 shares. Before that another transaction happened on Nov 22 ’24, when Company’s President and CEO sold 48,967 for $21.10, making the entire transaction worth $1,033,204. This insider now owns 1,989,007 shares in total.
Adma Biologics Inc (ADMA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 496.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.00% during the next five years compared to 38.68% growth over the previous five years of trading.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
You can see what Adma Biologics Inc (ADMA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.56. Likewise, its price to free cash flow for the trailing twelve months is 60.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.28, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.74 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
Let’s dig in a bit further. During the last 5-days, its volume was 2.96 million. That was inferior than the volume of 3.61 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 34.17%. Additionally, its Average True Range was 1.01.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 71.56%, which indicates a significant increase from 37.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.64% in the past 14 days, which was lower than the 78.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.05, while its 200-day Moving Average is $12.94. However, in the short run, Adma Biologics Inc’s stock first resistance to watch stands at $20.01. Second resistance stands at $20.21. The third major resistance level sits at $20.53. If the price goes on to break the first support level at $19.49, it is likely to go to the next support level at $19.17. Assuming the price breaks the second support level, the third support level stands at $18.97.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
There are 236,390K outstanding shares of the company, which has a market capitalization of 4.81 billion. As of now, sales total 258,220 K while income totals -28,240 K. Its latest quarter income was 119,840 K while its last quarter net income were 35,910 K.
